The Role of Volatile Organic Compounds (VOCs), Airway Mucins and the Microbiome in the Early Prediction of Bronchopulmonary Dysplasia (BPD)

Recruiting Observational Study
Bronchopulmonary Dysplasia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 Days – 3 Days
Sex
Any
Study type
Observational
Participants needed
140 (estimated)
Sponsor
University Hospital, Antwerp · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Bronchopulmonary dysplasia (BPD), the most common respiratory complication of extremely preterm birth, significantly impacts healthcare with high morbidity and mortality rates. Despite the well-established primordial role of inflammation and oxidative stress in the development of BPD, clinical practice does not incorporate the testing for biomarkers associated with the development of BPD. The dia…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Born at a gestational age \< 30 weeks Exclusion Criteria: * Major congenital defect or disorder * Patients with an unstable general condition as deemed by the attending neonatologist
Contacts

Inès Ghys, MD

+3232655230

ines.ghys@uantwerpen.be

CONTACT

Kristien Vanhaverbeke, MD, PhD

CONTACT